ABBV-951 is subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease.

Type of Molecule

Small Molecule

Target

Dopamine Receptor

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Parkinson's Disease New Indication Phase 1